US Patent

US9233112 — Pharmaceutical compositions of cefixime

Method of Use · Assigned to Lupin Ltd · Expires 2028-12-14 · 3y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a pharmaceutical suspension dosage form of cefixime with a specific concentration range of 80-150 mg/ml.

USPTO Abstract

A pharmaceutical suspension dosage form comprising greater than 80 mg/ml and not more than 150 mg/ml of Cefixime and pharmaceutically acceptable excipients.

Drugs covered by this patent

Suprax (CEFIXIME)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1676`	—	Suprax

Patent Metadata

Patent number: US9233112
Jurisdiction: US
Classification: Method of Use
Expires: 2028-12-14
Drug substance claim: No
Drug product claim: Yes
Assignee: Lupin Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.